Safety and Performance of the SinuSys Dilation System for Dilation of the Maxillary Sinus Ostium
SinuSys Patency of Maxillary Sinus Ostia Study
1 other identifier
interventional
36
3 countries
5
Brief Summary
The purpose of this study is to assess safety and performance of the SinuSys Dilation System for dilation of the maxillary sinus ostium.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_1
Started Apr 2012
Typical duration for phase_1
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2012
CompletedFirst Submitted
Initial submission to the registry
June 13, 2012
CompletedFirst Posted
Study publicly available on registry
June 19, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2014
CompletedResults Posted
Study results publicly available
October 1, 2014
CompletedNovember 5, 2014
October 1, 2014
1.2 years
June 13, 2012
September 26, 2014
October 30, 2014
Conditions
Outcome Measures
Primary Outcomes (1)
Patency of Treated Area
Immediately post procedure
Secondary Outcomes (4)
Patency of Treated Area
3 months
Number of Participants With Device-related Adverse Events as a Measure of Safety
3 months
Patency of Treated Area
6 months
Patency of Treated Area
12 months
Study Arms (1)
SinuSys Dilation System
EXPERIMENTALMaxillary Sinus Dilation
Interventions
Eligibility Criteria
You may qualify if:
- Diagnosis of chronic maxillary sinusitis
You may not qualify if:
- Previous antrostomy
- Sinonasal tumours
- Cystic fibrosis
- History of facial trauma that distorts sinus anatomy and precludes access to the maxillary sinus
- Pregnant or breastfeeding females
- Currently participating in another drug or device study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (5)
Valley ENT
Tucson, Arizona, 85745, United States
Palo Alto Medical Foundation
Palo Alto, California, 94301, United States
St. Elizabeth Medical Center
Boston, Massachusetts, 02135, United States
St. Paul's Hospital, ENT Department
Vancouver, British Columbia, BC V6Z 1Y6, Canada
Charing Cross Hospital
London, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Janie Mandrusov, Director of Pre-Clinical and Clinical Development
- Organization
- SinuSys Corporation
Study Officials
- PRINCIPAL INVESTIGATOR
Peter Catalano, MD
St Elizabeth Medical Center
- PRINCIPAL INVESTIGATOR
Amin Javer, MD
St. Paul's Hospital
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- LTE60
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 13, 2012
First Posted
June 19, 2012
Study Start
April 1, 2012
Primary Completion
June 1, 2013
Study Completion
September 1, 2014
Last Updated
November 5, 2014
Results First Posted
October 1, 2014
Record last verified: 2014-10